


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT ENTERED INTO WITH CHINA INSTITUTE OF ATOMIC ENERGY

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company entered into a strategic cooperation agreement with China Institute of Atomic Energy on 7 April 2023.

Pursuant to the agreement, the two parties will, based on the principle of “complementary advantages, mutual benefits, win-win collaboration, common development”, focus on nuclear medicine, irradiation application and other fields to carry out comprehensive cooperation in various aspects such as technology R&D, production development, achievements transformation, platform building and industrialization development, in a joint effort to push forward the construction of major infrastructure projects relating to isotopes, strengthen independent supply capacities for key isotopes and improve the innovative R&D in isotopes, radiopharmaceuticals and radioactive sources, so as to promote the high-quality development of nuclear technology applications.

As the cradle of China’s nuclear science and technology as well as a base for basic and comprehensive nuclear research, China Institute of Atomic Energy has made historical contributions to the strategic planning, establishment and development of China’s nuclear technology undertakings. China Institute of Atomic Energy covers numerous research areas such as nuclear materials, nuclear power, advanced nuclear energy and nuclear fuel cycle, nuclear technology application, basic and generic technology, and has built four major science platforms including China Experimental Fast Reactor (CEFR) and China Advanced Research Reactor (CARR).

The Company has been maintaining a close partnership with China Institute of Atomic Energy in nuclear technology application for a long time and has obtained a series of iconic achievements. The signing of the strategic cooperation agreement marks the two parties will have a higher and deeper level of cooperation in a broader range of areas, which is of great strategic importance to the Company's future technical innovation and industrial development.

By order of the Board
China Isotope & Radiation Corporation
Wang Suohui
Chairman

Beijing, the PRC, 10 April 2023

As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Dai Shuquan, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Hui Wan Fai, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.